Some trades already at.3 Conservatively, not far from reaching .35 by Thursday .... Friday and the following Monday may be as fun as going to Schlitterbahn for the weekend then pounding the hard wood floor at Gruene Hall to Ray Willie Hubbard all in celebration of leronlimab finding new boots.
So now i find it interesting how Gilead is on a buying terror for Oncology. CYDY would be foolish not to license to them but that would take a bigger hunk of money than they are presently paying for acquisitions. They know what we got.
Two possibilities could be taking place. They are buyng early round oncology companies in 1-2b area which is pretty rare for yet to be proven drugs. Why? They may well be out of the competition for leronlimab and they are positioning best they can for what is coming in order to still be competitive, or they are waiting on the oncology report and presentations next week, then pounce.
Market Data 
Markets 
AI
